Mirvaso (Brimonidine Tartrate)

Brimonidine tartrate, the active ingredient in Mirvaso, is a Alpha-2 adrenergic agonist presented as a gel for topical use. It reduces persistent facial erythema of rosacea in adults by constricting superficial cutaneous blood vessels. GNH USA supplies Mirvaso as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirvaso is a topical alpha‑2 adrenergic agonist indicated for rosacea‑related facial redness. - Persistent facial erythema of rosacea: decreases visible redness and improves skin appearance in affected patients.

Adverse reactions may occur with topical use of Mirvaso.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site - Burning or stinging sensation - Dryness of the treated area - Pruritus (itching) - Erythema (transient redness) - Flushing

Serious or Rare Side Effects: - Allergic contact dermatitis: rash, swelling, or hives - Severe skin ulceration or necrosis - Systemic hypotension: dizziness or fainting - Ocular involvement if applied near the eyes - Anaphylaxis: rapid onset of airway swelling or difficulty breathing

Before using Mirvaso, consider the following safety measures. - Hypersensitivity: avoid if known allergy to brimonidine or formulation components - Broken skin: do not apply on open wounds or irritated skin - Cardiovascular disease: use with caution in patients prone to low blood pressure - Concomitant vasoconstrictors: monitor for additive effects when used with other topical vasoconstrictors - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional - Store at room temperature: keep in the original tube, protect from moisture and direct heat

Mirvaso may interact with other agents that affect vascular tone or blood pressure.

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine): risk of additive hypotension - Oral antihypertensives: may enhance blood‑pressure‑lowering effects

Moderate Interactions (Monitor Closely):\n- Other topical vasoconstrictors (e.g., oxymetazoline): increased local vasoconstriction risk - Concurrent rosacea therapies (e.g., topical antibiotics): monitor for irritation - Eye drops containing vasoconstrictors: avoid accidental ocular exposure